Company / EPS (Basic)
Vistagen Therapeutics, Inc. EPS (Basic) History
FY2014-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$7.38
FY2023
5-year range
-$7.38 / -$0.49
FY2019-FY2023
Trend
-1406.1%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) changed -1406% YoY in FY2023, a notable deviation from the 2-year average annual change of -672%.
Based on SEC 10-K filings.
-7.38 in FY2023.
Declined from $-1.27 to $-7.38 over the past 9 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, eps (basic) decreased 1406.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$7.38 | -1406.1% |
| FY2022 | -$0.49 | - |
| FY2021 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2014 | -$1.27 | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026